Noninvasive in vivo MRI detection of neuritic plaques associated with iron in APP[V717I] transgenic mice, a model for Alzheimer's disease
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Transgenic mice overexpressing the London mutant of human amyloid precursor protein (APP[V717I]) in neurons develop amyloid plaques in the brain, thus demonstrating the most prominent neuropathological hallmark of Alzheimer's disease. In vivo 3D T2*‐weighted MRI on these mice (24 months of age) revealed hypointense brain inclusions that affected the thalamus almost exclusively. Upon correlating these MRI observations with a panel of different histologic staining techniques, it appeared that only plaques that were positive for both thioflavin‐S and iron were visible on the MR images. Numerous thioflavin‐S‐positive plaques in the cortex that did not display iron staining remained invisible to MRI. The in vivo detection of amyloid plaques in this mouse model, using the intrinsic MRI contrast arising from the iron associated with the plaques, creates an unexpected opportunity for the noninvasive investigation of the longitudinal development of the plaques in the same animal. Thus, this work provides further research opportunities for analyzing younger APP[V717I] mouse models with the knowledge of the final outcome at 24 months of age. Magn Reson Med 53:607–613, 2005. © 2005 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876 · cited 1×
“According to the amyloid cascade hypothesis, the increased amyloid deposition results in the onset and progression of AD (2,3,4,5) and therefore amyloid plaques became crucial as a target for many therapeutic approaches (6,7).”
BackgroundScheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
Release of Excess Amyloid β Protein from a Mutant Amyloid β Protein Precursor
Cai, X.-D., Golde, T. E., & Younkin, S. G. (1993) · Science · doi:10.1126/science.8424174 · Cited by 913 · cited 2×
“According to the amyloid cascade hypothesis, the increased amyloid deposition results in the onset and progression of AD (2,3,4,5) and therefore amyloid plaques became crucial as a target for many therapeutic approaches (6,7).”
BackgroundCerebral Hemorrhage After Passive Anti-Aβ Immunotherapy
Pfeifer, M., Boncristiano, S., Bondolfi, L., Stalder, A., Deller, T., Staufenbiel, M., Mathews, P. M., & Jucker, M. (2002) · Science · doi:10.1126/science.1078259 · Cited by 511
Axonal transport, tau protein, and neurodegeneration in Alzheimer's disease
Terwel, D., Dewachter, I., & Van Leuven, F. (2002) · NeuroMolecular Medicine · doi:10.1385/nmm:2:2:151 · Cited by 146 · cited 1×
“According to the amyloid cascade hypothesis, the increased amyloid deposition results in the onset and progression of AD (2,3,4,5) and therefore amyloid plaques became crucial as a target for many therapeutic approaches (6,7).”
BackgroundSelf-citation
Cited by
Mueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C. R., Jagust, W., Trojanowski, J. Q., Toga, A. W., & Beckett, L. (2005) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2005.06.003 · Cited by 1,233
Metal Toxicity Links to Alzheimer's Disease and Neuroinflammation
Huat, T. J., Camats-Perna, J., Newcombe, E. A., Valmas, N., Kitazawa, M., & Medeiros, R. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.01.018 · Cited by 470
Cheng, K. K., Chan, P. S., Fan, S., Kwan, S. M., Yeung, K. L., Wáng, Y.-X. J., Chow, A. H. L., Wu, E. X., & Baum, L. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2014.12.005 · Cited by 293
Meadowcroft, M. D., Connor, J. R., Smith, M. B., & Yang, Q. X. (2009) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.21731 · Cited by 176
Cortical iron reflects severity of Alzheimer's disease
van Duijn, S., Bulk, M., van Duinen, S. G., Nabuurs, R. J. A., van Buchem, M. A., van der Weerd, L., & Natté, R. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161143 · Cited by 172
Mandel, S., Amit, T., Bar-Am, O., & Youdim, M. B. H. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.06.001 · Cited by 164
Gong, N.-J., Dibb, R., Bulk, M., van der Weerd, L., & Liu, C. (2019) · NeuroImage · doi:10.1016/j.neuroimage.2019.02.019 · Cited by 162
Micro MRI of the mouse brain using a novel 400 MHz cryogenic quadrature RF probe
Baltes, C., Radzwill, N., Bosshard, S., Marek, D., & Rudin, M. (2009) · NMR in Biomedicine · doi:10.1002/nbm.1396 · Cited by 152
In Vivo Magnetic Resonance Microimaging of Individual Amyloid Plaques in Alzheimer's Transgenic Mice
Jack, C. R., Wengenack, T. M., Reyes, D. A., Garwood, M., Curran, G. L., Borowski, B. J., Lin, J., Preboske, G. M., Holasek, S. S., Adriany, G., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2588-05.2005 · Cited by 148
Yang, J., Zaim Wadghiri, Y., Minh Hoang, D., Tsui, W., Sun, Y., Chung, E., Li, Y., Wang, A., de Leon, M., & Wisniewski, T. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.01.023 · Cited by 135
“Because the chemical constituents of senile plaques affect MRI signal, a small proportion of mature plaques with high levels of iron have been detected ex vivo and in vivowithout contrast agents in old transgenic mice by μMRI (Borthakur et al., 2006; Braakman et al., 2006; Helpern et al., 2004; Jack et al., 2004; Lee…”
BackgroundIn Vivo mouse imaging and spectroscopy in drug discovery
Beckmann, N., Kneuer, R., Gremlich, H., Karmouty‐Quintana, H., Blé, F., & Müller, M. (2007) · NMR in Biomedicine · doi:10.1002/nbm.1153 · Cited by 118
Wadghiri, Y. Z., Li, J., Wang, J., Hoang, D. M., Sun, Y., Xu, H., Tsui, W., Li, Y., Boutajangout, A., Wang, A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057097 · Cited by 114
“Our studies corroborated reports by others using post-mortem AD brain tissue [20] and AD transgenic mouse brain tissue (ex vivo [21–23] and in vivo [22,24,25]).”
ResultA review of β-amyloid neuroimaging in Alzheimer's disease
Adlard, P. A., Tran, B. A., Finkelstein, D. I., Desmond, P. M., Johnston, L. A., Bush, A. I., & Egan, G. F. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00327 · Cited by 93
“…there have since been several more studies investigating amyloid imaging with GRE sequences as well as further applications of SE protocols (Vanhoutte et al., 2005; Borthakur et al., 2006; Braakman et al., 2006; Faber et al., 2007; Chamberlain et al., 2009; Dhenain et al., 2009;…”
BackgroundMethodResultInfluentialImaging of cerebrovascular pathology in animal models of Alzheimer's disease
Klohs, J., Rudin, M., Shimshek, D. R., & Beckmann, N. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00032 · Cited by 82
“…Wu et al., 2004 Inflammation (multiphoton microscopy) Koenigsknecht-Talboo et al., 2008 APP/London (APP(V717I)) Hypointense brain inclusions (MRI) Vanhoutte et al., 2005 J20 hAPP perfusion (ASL) Hébert et al., 2013 APP23 Vascular changes (MRA, fMRI) Mueggler et al., 2002, 2003; Beckmann et al.,…”
BackgroundAPP transgenic mice: their use and limitations
Balducci, C., & Forloni, G. (2011) · NeuroMolecular Medicine · doi:10.1007/s12017-010-8141-7 · Cited by 79
“Several groups have used MRI to document amyloid plaque pathology progression in humans and mice (Benveniste et al. 1999; Dhenain et al. 2002; Poduslo et al. 2002; Jack et al. 2004; Lee et al. 2004; Falangola et al. 2005; Vanhoutte et al. 2005; Jack et al. 2007; Wengenack et al. 2008).”
Andjus, P. R., Bataveljić, D., Vanhoutte, G., Mitrecic, D., Pizzolante, F., Djogo, N., Nicaise, C., Kengne, F. G., Gangitano, C., Michetti, F., et al. (2009) · The Anatomical Record · doi:10.1002/ar.20995 · Cited by 65
Self-citationWeidensteiner, C., Metzger, F., Bohrmann, A. B. B., Kuennecke, B., & von Kienlin, M. (2009) · Magnetic Resonance in Medicine · doi:10.1002/mrm.21985 · Cited by 56
“A decrease in T*2 was detected in the thalamus of APP[V717I] mice as compared to WT mice at age 2 years (40).”
MethodRegional differences in MRI detection of amyloid plaques in AD transgenic mouse brain
Wengenack, T. M., Reyes, D. A., Curran, G. L., Borowski, B. J., Lin, J., Preboske, G. M., Holasek, S. S., Gilles, E. J., Chamberlain, R., Marjanska, M., et al. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2010.08.033 · Cited by 41
“…have reported the ability to image AD amyloid plaques using magnetic resonance imaging (MRI) without the aid of a contrast-enhancing agent (Benveniste et al., 1999;Helpern et al., 2004; Jack et al., 2004, 2005; Lee et al., 2004; Poduslo et al., 2002; Vanhoutte et al., 2005; Zhang et al., 2004).”
BackgroundInfluentialAlzheimer's disease biomarkers: correspondence between human studies and animal models
Sabbagh, J. J., Kinney, J. W., & Cummings, J. L. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.04.010 · Cited by 27
“It is unclear how translatable these findings are to humanAD as large variability in plaquemetal content and arterial plaque binding complicates the interpretation of the data (Dhenain et al., 2002; Vanhoutte et al., 2005).”
BackgroundMagnetic Resonance Imaging of Amyloid Plaques in Transgenic Mouse Models of Alzheimers Disease
Chamberlain, R., M. Wengenack, T., F. Poduslo, J., Garwood, M., & R. Jack, C. (2011) · Current Medical Imaging Reviews · doi:10.2174/157340511794653522 · Cited by 26
“Thalamic plaques are highly visible by standard Perl's (Prussian blue) staining [24].”
Background
Metadata
- Authors
- Vanhoutte, G., Dewachter, I., Borghgraef, P., Van Leuven, F., & Van der Linden, A.
- Venue
- Magnetic Resonance in Medicine
- Publisher
- Wiley
- Published
- 2005-02-18
- Volume
- 53
- Issue
- 3
- Pages
- 607-613
- ISSN
- 0740-3194 (ISSN-L)
- 1522-2594
- OpenAlex
- W1978831666
- Cited by
- 138
- References
- 5
- FWCI
- 8.03
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.